AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05717907 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: suction catheter
Description: a suction catheter will be first inserted through the ETT so that about 10 cm of the catheter was protruding from the distal end of the tube. The tip of the catheter is then inserted through the selected nostril until it passes to the pharynx. If resistance is felt to the passage of catheter, the other nostril will be tried. The nostril with less resistance to the catheter passage will be chosen for the completion of the procedure. The Endotracheal tube is then advance over the catheter through the nasal passage while holding the catheter proximal to the tube to prevent its advancement with the tube. After the tube tip reach to the pharynx, the suction catheter is withdrawn and tracheal intubation will be completed.
Study NCT04846517 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Transcranial Magnetic Treatment
Description: iTBS treatment: Trains of 50 Hz pulses every 200 ms lasting 2 s, with an 8 s intertrain interval (ITI), repeated 60 times 1800 total pulses each day Treatment Duration: 9 minutes Location: Left DLPFC~LF-rTMS treatment: Delivered immediately after iTBS treatment as described above.~SMA will involve a continuous train of 1 Hz stimulation for a total of 1200 pulses lasting 20 minutes Treatment Duration: 20 minutes Location: SMA
Study NCT05005520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DTRI-031
Description: Investigational drug
Study NCT05005520 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to DTRI-031
Study NCT05274685 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: haemodialysis
Description: continuous venovenous hemodiafiltration (CVVHDF) at a prescribed dose of 30-35 mL/kg/h of effluent and with regional citrate anticoagulation
Study NCT06696482 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 10 mg
Description: Placebo 10 mg, encapsulated in an opaque capsule to facilitate blinding of participant and researcher
Study NCT06696846 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD70 CAR-NK
Description: CAR - NK cells constructed by using genetic engineering technology retain the original extensive tumor - killing ability of NK cells. By using their unique target cell recognition mechanism, the target is accurately locked on specific antigen proteins, thereby enhancing the anti - tumor effect. Cord blood-derived CAR - NK cell products shorten the treatment time and are inexpensive. Multiple studies have confirmed the feasibility of CAR - NK cells in treating hematological tumors.~Blocking the CD70/CD27 signaling pathway plays an important role in inhibiting CD70 - positive tumors, such as refractory/relapsed T - cell lymphoma and acute myeloid leukemia. Pre - clinical studies in our laboratory have proved that CD70 CAR - NK can effectively inhibit the in - vivo and in - vitro proliferation of T - cell lymphoma and prolong survival.
Study NCT06698068 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Equine-assisted therapy
Description: 15 equine therapy sessions, twice a week, over 7 to 8 weeks. Each session will last 60 minutes, including various activities such as emotional expression, contact with the horse, grooming, activities on foot or on horseback, and a debriefing time.
Study NCT06398626 — intervention group
Intervention type: DRUG
Intervention: Etrasimod
Description: As provided in real world practice
Study NCT06211257 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dematerialized Personalized Care Plan (ePCP)
Description: Post-treatment support with standard support combined with dematerialized support
Study NCT05523960 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: No MBP
Description: No mechanical bowel preparation before operation
Study NCT05523960 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No MBP
Description: No mechanical bowel preparation before operation
Study NCT05001191 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gentle Human Touch
Description: Gentle human touch, which has a pain and stress-reducing effect, is a sensitive tactile stimulus applied to the skin, without caress or massage, which provides a kind of relaxation.
Study NCT04836182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IONIS-AGT-LRx
Description: Multiple doses of IONIS-AGT-LRx will be administered by SC injection.
Study NCT04836182 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IONIS-AGT-LRx-matching placebo will be administered by SC injection.
Study NCT06147258 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: expressive writing
Description: A typical session will begin with the teaching artist (i.e., writing coach) introducing a new writing theme. Participants will have at least 20 minutes to write, and each session will include post-writing reflections and sharing, an undirected supportive interaction among participants.
Study NCT05619796 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulpectomy procedure
Description: single visit pulpectomy was performed under strict aseptic conditions by a single operator. Peri-operative evaluation was done using intraoral digital senso. The teeth were anesthetized with 2% mepivacaine with 1:20,000 levonordefrin \& isolated using rubber dam. caries was removed using no. 330 round carbide burs in high-speed contra angle headpiece. Access opening was gained \& the roof of the pulp chamber was removed. Working length was determined by apex locator, then confirmed by periapical radiograph. Working length will be determined 1 mm shorter than apex. mechanical preparation was done using the tested files according to each group. Then, canals were irrigated with 1% sodium hypochlorite between each file followed by irrigation with normal saline. The root canals were dried using paper points \& root canals were filled with Metapex. Intermediate restorative material was placed, and the tooth was restored with a preformed stainless-steel crown in the same appointment.
Study NCT05619796 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pulpectomy procedure
Description: single visit pulpectomy was performed under strict aseptic conditions by a single operator. Peri-operative evaluation was done using intraoral digital senso. The teeth were anesthetized with 2% mepivacaine with 1:20,000 levonordefrin \& isolated using rubber dam. caries was removed using no. 330 round carbide burs in high-speed contra angle headpiece. Access opening was gained \& the roof of the pulp chamber was removed. Working length was determined by apex locator, then confirmed by periapical radiograph. Working length will be determined 1 mm shorter than apex. mechanical preparation was done using the tested files according to each group. Then, canals were irrigated with 1% sodium hypochlorite between each file followed by irrigation with normal saline. The root canals were dried using paper points \& root canals were filled with Metapex. Intermediate restorative material was placed, and the tooth was restored with a preformed stainless-steel crown in the same appointment.
Study NCT05619796 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Post-operative Cone Beam Computed Tomography
Description: post-operative CBCT image was taken after completing the procedure with fixed exposure parameters (120 Kv, 5mA and 0.125mm voxel size) using smallest field of view (8D, 8Hcm) to improve spatial resolution. The CBCT images were obtained by using 3D module of On Demand Dental software (version 1.0 (build 1.0.10.7462),× 64 Edition, copyright 2004-2017 Cybermed, Korea and license key 670094709).~The Immediate post-operative CBCT was taken to evaluate the quality of root canal filling by two trained pediatric dentists, blinded to instrumentation technique .
Study NCT05619796 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Post-operative Cone Beam Computed Tomography
Description: post-operative CBCT image was taken after completing the procedure with fixed exposure parameters (120 Kv, 5mA and 0.125mm voxel size) using smallest field of view (8D, 8Hcm) to improve spatial resolution. The CBCT images were obtained by using 3D module of On Demand Dental software (version 1.0 (build 1.0.10.7462),× 64 Edition, copyright 2004-2017 Cybermed, Korea and license key 670094709).~The Immediate post-operative CBCT was taken to evaluate the quality of root canal filling by two trained pediatric dentists, blinded to instrumentation technique .
Study NCT05619796 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-operative pain assessment
Description: The parents of the children were given a questionnaire to record the intensity of postoperative pain at six, twelve, twenty-four and forty-eight hours after the pulpectomy procedure. A nursing officer who was blind to the study groups, had trained all parents on how to record the postoperative pain. The four-point pain intensity scale was used to record postoperative pain (figure 5). This scale categorizes pain as follows: (1) no pain; (2) slight pain; (3) moderate pain; and (4) severe pain. To ensure standardization, the same parent was asked to record the child's pain intensity at all time intervals. To reduce the possibility of the parents failing to record the pain at a given time, the investigator also recorded findings via telephonic conversation with the parents. The children returned to the department two days after the pulpectomy procedure with their completed questionnaire form.
Study NCT05619796 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post-operative pain assessment
Description: The parents of the children were given a questionnaire to record the intensity of postoperative pain at six, twelve, twenty-four and forty-eight hours after the pulpectomy procedure. A nursing officer who was blind to the study groups, had trained all parents on how to record the postoperative pain. The four-point pain intensity scale was used to record postoperative pain (figure 5). This scale categorizes pain as follows: (1) no pain; (2) slight pain; (3) moderate pain; and (4) severe pain. To ensure standardization, the same parent was asked to record the child's pain intensity at all time intervals. To reduce the possibility of the parents failing to record the pain at a given time, the investigator also recorded findings via telephonic conversation with the parents. The children returned to the department two days after the pulpectomy procedure with their completed questionnaire form.
Study NCT05425797 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In-Person Prevention Practitioner Visit
Description: BETTER Intervention visit with PP which will take place in-person at the PP's office.
Study NCT05425797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video-Call Prevention Practitioner Visit
Description: BETTER Intervention visit with PP which will take place virtually via a secure video system.
Study NCT04870034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Given PO
Study NCT04870034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO
Study NCT04870034 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT05385185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab or envafolimab
Description: combine Camrelizumab or envafolimab with Recombinant human vascular endostatin
Study NCT06002958 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Horyzons USA
Description: Client participants will be onboarded to the digital platform, including the different spaces and how to use the site. The site includes therapeutic content that is tailored to each individual and their current needs and experiences, including social anxiety, generalized anxiety, mood, and social functioning, and distress intolerance. Further, the platform includes a moderated social media function, where individuals and peer support specialists can post text, images, videos, and comments to connect and share their experiences. The site is monitored by graduated students and trained clinicians.
Study NCT05425797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone Prevention Practitioner Visit
Description: BETTER Intervention visit with PP which will take place via telephone.
Study NCT04926324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib is a drug FDA-approved for use in maintenance treatment of adults with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
Study NCT05586724 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Micronized progesterone in continuous combination with oral estrogen
Description: Capsule 100 mg mP (Utrogestan®) orally per day in continuous combination with 1 mg encapsulated estradiol (Estrofem®)
Study NCT05586724 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norethisterone acetate in continuous combination with oral estrogen
Description: Capsule 0.5 mg NETA/ 1 mg estradiol (Activelle®) orally per day (encapsulated and identical to Estrofem® and one matched placebo to Utrogestan
Study NCT05396950 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: CPAP in conjunction with radiotherapy
Study NCT04926324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab, sold under the brand name Jemperli, is a monoclonal antibody medication used for the treatment of endometrial cancer.
Study NCT04926324 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short course radiation
Description: Participants will be treated with intensity modulated radiation therapy (IMRT) or volumetric modulated arc therapy (VMAT) to minimize mean dose to femoral, pelvic, and lumbar bone marrow. The entire mesorectum will be treated to a total dose of 25 Gy.
Study NCT05098951 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Patients with stiffness of joint receive acupuncture therapy twice weekly for 6 weeks and then once weekly for 6 weeks.
Study NCT03205137 — intervention group
Intervention type: DRUG
Intervention: subjects treated with telmisartan/hydrochlorothiazide
Description: subjects treated with telmisartan/hydrochlorothiazide
Study NCT03205137 — intervention group
Intervention type: DRUG
Intervention: Subjects treated with Telmisartan and amlodipine
Description: Subjects treated with Telmisartan and amlodipine
Study NCT03205137 — intervention group
Intervention type: DRUG
Intervention: subjects treated with Telmisartan+hydrochlorothiazide double-pill combination group
Description: subjects treated with Telmisartan+hydrochlorothiazide double-pill combination group
Study NCT03205137 — intervention group
Intervention type: DRUG
Intervention: subjects treated with telmisartan+amlodipine double pill
Description: subjects treated with telmisartan+amlodipine double pill
Study NCT05674175 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)
Description: CART22-65s are autologous T cells that have been engineered to express an extracellular single chain antibody (scFv) with specificity for CD22 linked to an intracellular signaling molecule consisting of a tandem signaling domain comprised of the TCRζ signaling module linked to the 4-1BB costimulatory domain
Study NCT05674175 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)
Description: HuCART19 cells are autologous T cells that have been engineered to express an extracellular single chain antibody (scFv) with specificity for CD19 linked to an intracellular signaling molecule consisting of a tandem signaling domain comprised of the TCRζ signaling module linked to the 4-1BB costimulatory domain
Study NCT05584371 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Free Beta-hydroxybutyrate
Description: Participants will be asked to ingest 10 grams of beta-hydroxybutyrate, diluted in water and sweetened with Stevia, every morning between 9:00 and 11:00 for four weeks.
Study NCT06170489 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS004 in combination with Toripalimab
Description: Participants will receive JS004 in combination with Toripalimab (200 mg/240 mg) by intravenous (IV) infusion on Day 1, then every three weeks (Q3W), for up to 35 infusions.
Study NCT06170489 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine or gemcitabine
Description: Participants will receive Investigator-Selected chemotherapy of EITHER bendamustine by IV infusion at a dose of 90 or 120 mg/m\^2 on Day 1 and Day 2 of either a 3- or 4-week cycle for up to 6 cycles OR gemcitabine by IV infusion at a dose of 1000 mg/m\^2 on Day 1 and Day 8 of a 3-week cycle for up to 6 cycles.
Study NCT06103461 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous fat grafting
Description: Autologous fat grafted at contour defects with pigmentary changes
Study NCT05588882 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wavefront-guided LASIK
Description: Topography-guided utilizes topography mapping to perform the ablation
Study NCT05588882 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wavefront-guided
Description: Wavefront-guided utilizes aberrometry to perform the ablation
Study NCT04920214 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SonoVue
Description: CEUS examination was performed and corresponding image information of liver lesions was obtained.
Study NCT06298630 — intervention group
Intervention type: OTHER
Intervention: Assessments
Description: Safety and efficacy assessments
Study NCT04236128 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobile App
Description: The app will be provided to patients in hospital on post-operative day 3. On the day of discharge, the patient will be emailed a Daily Health Check and receive subsequent Daily Health Check emails on Day 1-14, 21 and 30 days following discharge. The Daily Health Check is a tailored questionnaire to elicit their symptoms and status of post-operative recovery. After the patient has completed the Daily Health Check, a Daily Health Check Summary is emailed to the patient that summarizes their responses and provides appropriate action recommendations based on their responses ranging from: (i) suggestions for educational modules, (ii) expect a call from your health care team in the next 24 hours, (iii) call your surgeon's office today or (iv) go to the nearest emergency room. The patient's Daily Health Check responses are displayed in real time on a secure website that automatically red flags extreme responses to alert the health care team to contact the patient by telephone.
Study NCT04236128 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile App
Description: The app will be provided to patients in hospital on post-operative day 3. On the day of discharge, the patient will be emailed a Daily Health Check and receive subsequent Daily Health Check emails on Day 1-14, 21 and 30 days following discharge. The Daily Health Check is a tailored questionnaire to elicit their symptoms and status of post-operative recovery. After the patient has completed the Daily Health Check, a Daily Health Check Summary is emailed to the patient that summarizes their responses and provides appropriate action recommendations based on their responses ranging from: (i) suggestions for educational modules, (ii) expect a call from your health care team in the next 24 hours, (iii) call your surgeon's office today or (iv) go to the nearest emergency room. The patient's Daily Health Check responses are displayed in real time on a secure website that automatically red flags extreme responses to alert the health care team to contact the patient by telephone.
Study NCT05708417 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: The intervention in SDOI has the predominantly focus on each individual reflection and realisation and is built upon ACT' six core processes: 1) Acceptance, 2) Cognitive defusion 3) Being present, 4) Self as context, 5) Values, and 6) Committed action.~The program is based on up to 13 times attendance within the 12 months intervention period.
Study NCT05708417 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No lifestyle intervention within the study, only test/datacollection
Study NCT06609902 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Future Self-BD
Description: The Future Self group will attend 6 virtual sessions during which they will be encouraged to vividly generate personal and positive future events that they anticipate may be benefited by smoking cessation. All participants will complete the adjusting amount discounting task. All participants will also receive brief, CBT-based smoking cessation counseling. This group will involve one follow-up session one month after the sixth session. Each session will be conducted on HIPAA-compliant Zoom and led by the PI, Dr. Gold.
Study NCT06081400 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Percutaneous imaging-guided cryoablation
Study NCT06081400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy drug
Description: Either :~methotrexate 30mg/m² + vinblastine 6mg/m² (IV infusion) once/week for 6 months, then every other week from months 7 to 12, or vinorelbine 90mg/week (per os: 3x30mg, soft capsules) for 12 months.
Study NCT06609902 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Daily Check-Ins
Description: The Daily Check-Ins (DCI) group will attend 6 virtual sessions during which they will complete the adjusting amount discounting task and receive brief, CBT-based smoking cessation counseling (consistent with counseling received by Future Self-BD). This group will involve one follow-up session one month after the sixth session. Each session will be conducted on HIPAA-compliant Zoom and led by the PI, Dr. Gold.
Study NCT06217068 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Elliptical Activity
Description: 8 minutes of elliptical exercise at a moderate intensity based on heart rate reserve. There will be a 2-minute warm-up and 2-minute cool down period in addition to the 8 minutes at moderate-intensity.